Back to today’s briefing

Story perspectives

FDA Approves Fujirebio's Revolutionary Alzheimer's Blood Test

5/21/2025

50 10

Summary

Story summary

Fujirebio Diagnostics has made history with the FDA's approval of its groundbreaking blood test for Alzheimer's disease, the Lumipulse G pTau217/?-Amyloid 1-42. Designed for those aged 55 and older showing cognitive symptoms, this test helps identify amyloid plaques, yet it emphasizes the need for additional clinical evaluation to confirm a diagnosis.

1 of 1

Story summary

Fujirebio Diagnostics has made history with the FDA's approval of its groundbreaking blood test for Alzheimer's disease, the Lumipulse G pTau217/?-Amyloid 1-42. Designed for those aged 55 and older showing cognitive symptoms, this test helps identify amyloid plaques, yet it emphasizes the need for additional clinical evaluation to confirm a diagnosis.